$CMPX: A Major Cancer Drug Presentation at ESMO 2026 — Why Investors Are Watching

October 20, 2026 | Biotech Catalyst Watch

Compass Therapeutics, Inc. (NASDAQ: CMPX), a clinical-stage biopharmaceutical company focused on developing antibody-based cancer treatments, is scheduled to present results from its Phase 2/3 COMPANION-002 clinical trial at the European Society for Medical Oncology (ESMO) Congress 2026.

The presentation will focus on tovecimig (CTX-009), an investigational cancer therapy being evaluated in patients with previously treated advanced biliary tract cancer.

The ESMO Congress will take place October 23–27, 2026, in Madrid, Spain.

ESMO Presentation Details

Compass Therapeutics announced on July 17, 2026, that its clinical trial abstract had been selected for an oral Proffered Paper presentation.

The scheduled presentation details are:

• Presentation date: Saturday, October 24, 2026

• Session time: 10:15 AM–11:45 AM, Madrid time

• Presenter: Dr. Nilofer Azad, Johns Hopkins University

• Clinical trial: COMPANION-002

• Development stage: Phase 2/3

• Investigational therapy: Tovecimig (CTX-009) combined with paclitaxel

• Indication: Previously treated advanced biliary tract cancer

The presentation will cover results from the randomized, controlled study comparing tovecimig plus paclitaxel with paclitaxel alone.

About Tovecimig (CTX-009)

Tovecimig is an investigational bispecific antibody designed to target DLL4 and VEGF-A, two proteins involved in the development of blood vessels that support tumor growth.

The drug is being studied as a potential treatment for biliary tract cancer, a group of cancers affecting the bile ducts and related structures.

Patients with advanced biliary tract cancer who experience disease progression after initial treatment often have limited treatment options.

Compass Therapeutics is evaluating whether the addition of tovecimig to paclitaxel can improve treatment outcomes in this patient population.

Previously Reported COMPANION-002 Clinical Results

Compass Therapeutics previously announced results from the COMPANION-002 study, including statistically significant improvements in objective response rate and progression-free survival.

The final analysis reported the following findings:

Clinical measure	Tovecimig + paclitaxel	Paclitaxel alone
Objective response rate	18.0%	5.3%
Median progression-free survival	4.7 months	2.6 months
Median overall survival	8.9 months	9.4 months

The objective response rate measures the percentage of patients whose tumors shrink by a predefined amount.

Progression-free survival measures the time patients live without their cancer worsening.

The study met its primary endpoint of objective response rate, with a reported p-value of 0.0228. Progression-free survival also improved significantly, with a hazard ratio of 0.44 and a p-value below 0.0001.

However, the trial did not demonstrate a statistically significant improvement in overall survival.

Compass reported that 54% of patients in the control group crossed over to receive tovecimig plus paclitaxel after disease progression, complicating the interpretation of overall survival results.

These findings form an important part of the company's ongoing regulatory discussions.

FDA Feedback on Tovecimig

On September 22, 2026, Compass Therapeutics provided an update regarding discussions with the U.S. Food and Drug Administration (FDA).

According to the company, the FDA recommended an additional clinical trial demonstrating an overall survival benefit before Compass submits a Biologics License Application (BLA) for tovecimig.

Compass stated that it does not believe another trial is warranted before submission, based on the COMPANION-002 findings and the unmet medical need among patients with advanced biliary tract cancer.

The company indicated that it intends to continue discussions with the FDA while preparing a potential BLA submission.

As of October 20, 2026, tovecimig remains investigational and has not received FDA approval.

The upcoming ESMO presentation is a scientific conference event and should not be confused with an FDA regulatory decision.

Compass Therapeutics' Financial Position

In its second-quarter financial report released August 6, 2026, Compass Therapeutics reported approximately $180 million in cash and marketable securities as of June 30, 2026.

The company indicated that its available financial resources were expected to support operations into 2028.

This financial position provides resources for ongoing clinical development and regulatory activities, although future financing requirements will depend on the company's development plans and operating expenses.

Other Clinical Programs

In addition to tovecimig, Compass Therapeutics has other investigational antibody therapies in clinical development.

CTX-8371 is a bispecific antibody targeting PD-1 and PD-L1. The company is conducting Phase 1 clinical development, including cohort expansions involving several cancer types.

CTX-10726 is a bispecific antibody targeting PD-1 and VEGF-A. The program entered Phase 1 clinical testing, with initial data expected during the fourth quarter of 2026.

These programs represent additional clinical development activities beyond the company's COMPANION-002 study.

What to Expect From the ESMO Presentation

The October 24 presentation will provide an opportunity for Compass Therapeutics to discuss the COMPANION-002 results with an international audience of oncology researchers and healthcare professionals.

The presentation may provide additional details regarding the trial's efficacy, safety findings, subgroup analyses, and interpretation of the overall survival results.

The central questions surrounding tovecimig remain whether its demonstrated improvements in objective response rate and progression-free survival will support further regulatory progress, and how the FDA's request for additional overall survival evidence will be addressed.

No FDA approval decision is scheduled as part of the ESMO presentation.

Conclusion

Compass Therapeutics is scheduled to present its Phase 2/3 COMPANION-002 clinical trial results at ESMO 2026 on October 24.

The study demonstrated statistically significant improvements in objective response rate and progression-free survival for tovecimig plus paclitaxel compared with paclitaxel alone. However, the overall survival endpoint was not met, and the FDA has recommended additional evidence before a BLA submission.

The ESMO presentation will provide a scientific forum for reviewing these results as Compass continues development and regulatory discussions concerning tovecimig.

Disclaimer: This article is provided for informational and educational purposes only and does not constitute investment advice. Clinical-stage biotechnology companies face substantial clinical, regulatory, and financial risks. Readers should review official company announcements and regulatory filings before making investment decisions.